Search

Your search keyword '"Scher, Jose U."' showing total 14 results
Start Over Author "Scher, Jose U." Journal journal of rheumatology
14 results on '"Scher, Jose U."'

2. Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study

Author

Webster, Dan E., Haberman, Rebecca H., Perez-Chada, Lourdes M., Tummalacherla, Meghasyam, Tediarjo, Aryton, Yadav, Vijay, Neto, Elias Chaibub, MacDuffie, Woody, DePhillips, Michael, Sieg, Eric, Catron, Sydney, Grant, Carly, Francis, Wynona, Nguyen, Marina, Yussuff, Muibat, Castillo, Rochelle L., Yan, Di, Neimann, Andrea L., Reddy, Soumya M., Ogdie, Alexis, Kolivras, Athanassios, Kellen, Michael R., Mangravite, Lara M., Sieberts, Solveig K., Omberg, Larsson, Merola, Joseph F., and Scher, Jose U.

Abstract

ObjectivePsoriatic disease remains underdiagnosed and undertreated. We developed and validated a suite of novel, sensor-based smartphone assessments (Psorcast app) that can be self-administered to measure cutaneous and musculoskeletal signs and symptoms of psoriatic disease.MethodsParticipants with psoriasis (PsO) or psoriatic arthritis (PsA) and healthy controls were recruited between June 5, 2019, and November 10, 2021, at 2 academic medical centers. Concordance and accuracy of digital measures and image-based machine learning models were compared to their analogous clinical measures from trained rheumatologists and dermatologists.ResultsOf 104 study participants, 51 (49%) were female and 53 (51%) were male, with a mean age of 42.3 years (SD 12.6). Seventy-nine (76%) participants had PsA, 16 (15.4%) had PsO, and 9 (8.7%) were healthy controls. Digital patient assessment of percent body surface area (BSA) affected with PsO demonstrated very strong concordance (Lin concordance correlation coefficient [CCC] 0.94 [95% CI 0.91-0.96]) with physician-assessed BSA. The in-clinic and remote target plaque physician global assessments showed fair-to-moderate concordance (CCCerythema0.72 [0.59-0.85]; CCCinduration0.72 [0.62-0.82]; CCCscaling0.60 [0.48-0.72]). Machine learning models of hand photos taken by patients accurately identified clinically diagnosed nail PsO with an accuracy of 0.76. The Digital Jar Open assessment categorized physician-assessed upper extremity involvement, considering joint tenderness or enthesitis (AUROC 0.68 [0.47-0.85]).ConclusionThe Psorcast digital assessments achieved significant clinical validity, although they require further validation in larger cohorts before use in evidence-based medicine or clinical trial settings. The smartphone software and analysis pipelines from the Psorcast suite are open source and freely available.

Published
2024
Full Text
View/download PDF

5. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.

Author

Stober, Carmel, McInnes, Iain B., Raychaudhuri, Soumya, Mease, Philip J., Pennington, Stephen R., Scher, Jose U., Chandran, Vinod, Armstrong, April W., de Wit, Maarten, Cauli, Alberto, Jadon, Deepak R., Löve, Thorvardur J., Ogdie, Alexis, O'Sullivan, Denis, van Mens, Leonieke J. J., Ritchlin, Christopher T., FitzGerald, Oliver, and Wit, Maarten de

Published
2022
Full Text
View/download PDF

10. GRAPPA 2020 Research Award Recipients.

Author

Castillo, Rochelle L., Di Yan, Ashhurst, Anneliese S., Elliott, Ashley, Angioni, Maria Maddalena, Scher, Jose U., Naik, Shruti, Neimann, Andrea, Byrne, Scott N., Payne, Richard J., FitzGerald, Oliver, Pennington, Stephen R., Cauli, Alberto, Chandran, Vinod, and Yan, Di

Published
2022
Full Text
View/download PDF

13. Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.

Author

Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, and Merola JF

Abstract

The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

Published
2021
Full Text
View/download PDF

14. Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.

Author

Stober C, Jadon DR, Armstrong AW, Chandran V, de Wit M, Helliwell PS, Mease P, Ogdie A, O'Sullivan D, Pennington SR, Löve T, Cauli A, van Mens L, Waxman R, Scher JU, Barton A, Ritchlin CT, and FitzGerald O

Abstract

At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results